Craigakess you have faith if you want to admit it or not
Craigakess you have faith if you want to admit it or not that’s your business. You wouldn’t be here if you didn’t see the up side of this investment. As for realist? Naw... a realist would see the multiple paths this drug has and would acknowledge just how special things could be. As for “also ran” I hardly think you can label Leronlimab a defeated drug. It’s more of a fledgling drug just getting its wings. That’s the realist look at Leronlimab.
It’s going to be a wild ride with so much damn potential you would not sell a share to short your investment before the pending approval happens. Like you. I am green and not worried and have an average of .34/share. Worried... nope. Have time... yep... as we all do. But how much more time will we need to get our Covid approval?
To dismiss Covid is silly. We have 70-75% of all future hospital treated patients in Long Haulers. Nobody else trialing yet for that LH group. We are in a class by ourself on Severe/Critical. Once you get past the viral stage it’s all Leronlimab and people will know this. Why? Because once we get any form of EUA and a few papers written in journals come to light. Everyone will know the MAB that is the one you want. The one that stops the cytokine storm and stops the viral load. Then does this little immune system reset. This is what separates Leronlimab from all others. The immune response gets reversed and it turns negative cells to positive cells and no other drug trialed does this. Dare I say... we are in a class all by ourself. Do we need to compete with other drugs? Ok... a little competition but REALITY is they are not really competition. They are wannabes like Dr. Patterson said in his Tedx Talk. They are piece meal and nothing like the 3 functions of Leronlimab. Where one drug it would seem is designed for covid. There will be drugs and there will be winners and losers. I would not bet on Leronlimab as a loser. Or a “also ran”. Maybe you should watch Dr. Patterson’s TEDx Talk again. It’s pinned at the top of this page. He thinks we are in a different class all together. I have nothing but respect for Dr. Patterson. He made me a believer. He is a well respected man on this board and as professional as they come as a teacher. Watch his video and learn. It’s good remedial information in case you have forgotten any of the important points he makes.
11
2
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Tripadvisor's Stock Dive: Investor Panic or Opportunity? Woah, if you had a stake in Tripadvisor (NASDAQ: TRIP) recently, you know it hasn't been a walk in the park. Shares took a nosedive of over 20% on November 5, 2026, after they unveiled a frightening $313.1 million net loss for the third quarter. What stirred the pot, you ask? Well, toss in a goodwill impairment...
Continue Reading
Cavli Wireless: Paving the Path for Smarter IoT There's a storm brewing in Munich at electronica 2026, and Cavli Wireless is the name spurred across tech-savvy lips. With their latest revelation—the P16QS LTE Cat 1bis module and Cortex AI—the firm’s tossing bold challenges at the IoT and AI landscape. It's a gutsy move, cementing their role as a frontier pusher in a...
Continue Reading
A Quiet Giant Grows Stronger Who would've thought? While most folks are caught up watching tech stocks or energy commodities spike, NativeSeed Group just made a move worth raising an eyebrow over. On November 5, 2026, they scooped up the assets of Sharp Brothers Seed Company, a small firm in Healy, Kansas known for top-tier native seed cleaning. We've got ourselves a...
Continue Reading
Durham's Pride in Legal Excellence Just like ol' reliable clockwork, James Scott Farrin has clinched another honor that makes the legal landscape take note. This Durham-based law office, a heavyweight in the injury claims scene, isn't just shuffling papers; they're racking up accolades on the list of 'Best Law Firms' for the 12th year running. Now, that's no small feat....
Continue Reading
All Eyes on Curis as Q3 Financials Loom Just when you think you’ve seen it all in this wild biotech ride, Curis, Inc. (NASDAQ: CRIS) is prepping to roll out their third quarter financial and operating results. Circle your calendars for November 12, 2026, because the clock’s ticking down to their 4:00 p.m. ET announcement, swiftly followed by a conference call at 4:30...
Continue Reading
Unlocking the Science of Dietary Bioactives Amidst a world swimming in kale smoothies and exotic teas, ILSI U.S. & Canada gathered the sharpest minds to discuss dietary bioactives, an area once shrugged off but now coming into its own. On October 28, 2026, over 250 folks from government, academia, and industry tuned in, looking to understand how these compounds, found in...
Continue Reading
3D Systems' Earnings Leave Investors on Edge Like a hot potato, 3D Systems’ latest earnings report has investors feeling jittery. And with good reason–their third-quarter numbers are a mixed bag as they somehow squeezed out a positive $3.1 million in adjusted EBITDA and yet posted a yawning $33.5 million GAAP net loss. No wonder heads are spinning over at SueWallSt,...
Continue Reading
Breeze Airways and AIP's Milestone Deal Just as the ink is drying on the balance sheets, Breeze Airways is busy making significant moves in the aviation game. Partnering with AIP Capital, they just locked in a $228 million secured debt facility to grab six new Airbus A220-300 aircraft. Now, that’s how you stake your claim in the market. What we’ve got here isn’t...
Continue Reading
Revving Up the Golf Cart Market The golf cart market's looking like it's gearing up for one heck of a drive. Mordor Intelligence just dropped a report claiming we're gonna see the market haul itself from USD 2.44 billion in 2026 to USD 3.24 billion by 2031. That’s a tidy little jump with a CAGR of 5.81%. Blame it on electric mobility's allure, spruced-up lithium battery...
Continue Reading
Can't Ignore Ford's New Strategy in Pre-Owned Cars The auto industry may feel like a runaway train sometimes, and keeping up with the latest turns can be a headache. But here's something catching my eye: Chris Auffenberg Ford's new move with the Ford Blue Advantage certified pre-owned vehicles. It's not just any run-of-the-mill used car deal—this one's got some beef...
Continue Reading
Top 5 Most Recently Viewed Articles
Dr. Michelle L. Costa Joins National Health Care Associates In a notable recognition, Dr. Michelle L. Costa has become a Pinnacle Professional Member Inner Circle of Excellence for her outstanding contributions to healthcare leadership, especially in the realm of long-term care. With her recent appointment as Chief Clinical Officer at National Health Care Associates...
Continue Reading
Rackspace's Legal Predicament: Time for Action Alright folks, if you're holding shares of Rackspace Technology (NASDAQ:RXT), it’s time to sit up and pay attention. This is about more than bad PR or a temporary hiccup in the stock price—this is serious business. We’ve got until September 28, 2026, to decide if we’re in or out on this class action lawsuit train....
Continue Reading
CME Group to Honor Former President with Early Market Closure CME Group, a leading derivatives marketplace, is making headlines as it prepares for an early market closure in recognition of a significant event. The company, known for its robust market performance—including a notable 13% revenue growth over the past year—will adjust its trading hours to honor the...
Continue Reading
Sunshine Silver's Bold Leap Forward Fresh off the press: Sunshine Silver Mining & Refining's Q2 results show they're not shying away from the spotlight. This quarter was a game-changer for them, with a successful IPO on the NYSE, raised nearly $300 million, and no debt. Quite the hat trick, and it's setting the stage for their ambitions to ramp up production at their...
Continue Reading
Trading of Class A Ordinary Shares and Rights Begins Mountain Lake Acquisition Corp. (NASDAQ: MLAC) has exciting news for its investors. Starting from a specified date, holders of the units sold during the company's initial public offering will have the opportunity to separately trade their Class A ordinary shares and accompanying rights. This move signals a new chapter...
Continue Reading